Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA UCSD
Dates
study started
completion around

Description

Summary

Official Title

A Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530, an Autologous Logic-gated Tmod™ Chimeric Antigen Receptor T Cell (CAR T), in Heterozygous HLA-A*02 Adult Subjects With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Details

Keywords

Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer, CAR T Cell, Solid Tumors, autologous, T cell, Carcinoembryonic Antigen, CEA, HLA-A2, Solid Tumors Expressing CEA, PANC, Non-Small Cell Lung Cancer, Neoplasms, Lung Neoplasms, Non-Small-Cell Lung Carcinoma, Recurrence, xT-Onco with HLA-LOH Assay

Eligibility

Locations

  • University of California San Diego
    La Jolla California 92093 United States
  • UCLA Medical Center
    Los Angeles California 90404 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
A2 Biotherapeutics Inc.
Links
A2 Biotherapeutics Inc.
ID
NCT05736731
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 160 study participants
Last Updated